Impressive results in a subset of cancers have been obtained using immunotherapies such as checkpoint inhibitors (i.e. anti-CTLA4, anti-PD-1, and anti-PD-L1) and CAR T therapies. This evidence concerns the gene CTLA4 and cancer.